Information Provided By:
Fly News Breaks for October 16, 2019
FOMX
Oct 16, 2019 | 06:03 EDT
Barclays analyst Balaji Prasad highlights Foamix Pharmaceuticals' key upcoming FDA action date of October 20 for FMX-101 in acne. The analyst says ~75% of his $10 price target is derived from FMX-101, and that approval could add another $2, or 320% potential upside from current share levels. The analyst sees a 90% probability of success and forecasts 2025 risk adjusted sales of $202M. Prasad continues to like Foamix's risk/reward setup going into the October 20 PDUFA and he reiterates an Overweight rating on the shares.
News For FOMX From the Last 2 Days
There are no results for your query FOMX